Advertisement

Grey Matter Pathology in Multiple Sclerosis

  • B. P. Brink
  • S. J. Mork
  • P. Van Der Valk
  • L. Bo
Chapter
Part of the Topics in Neuroscience book series (TOPNEURO)

Abstract

Multiple sclerosis (MS) is a CNS disease histopathologically characterized by discrete areas of myelin, oligodendrocyte, and axonal loss [1]. The etiology of MS is unknown, but environmental factors and multiple separate genetic loci contribute to disease susceptibility. MS lesions may occur in all CNS parenchymal areas; the predilection sites include the optic nerve, brainstem, spinal cord, periventricular white matter, and subcortical areas. Although MS is frequently called a white matter disease, there is also myelin in grey matter, and grey matter demyelination is extensive in chronic MS [2–7]. This was evidenced even in early pathology studies, using histochemical staining methods for myelin detection [8–11]. The extent of cortical demyelination in MS has been studied in vivo using MRI and post mortem using histochemical or immunohistochemical techniques. Conventional MRI techniques may not be sensitive for cortical lesions, however: in a comparison of postmortem MRI and histological examinations, only 2 of 14 histologically detectable cortical lesions were detected by MRI [3]. In another, similar study none of the 39 cortical plaques identified histologically were detected by MRI, while in periventricular areas the maximum possible number of lesions detected by MRI often exceeded the number of histological plaques [12]. A recent study found a low sensitivity of MRI for purely cortical lesions compared with the grey matter part of combined white matter/grey matter lesions [7]. MRI sensitivity for deep grey matter lesions was slightly higher, at 10%–15% [7,12]. The reasons for the low sensitivity of conventional MRI could be (1) that the relaxation times of grey matter on T2-weighted images are close to the relaxation times of MS lesions, (2) partial volume effects due to the proximity to the CSF, and (3) less inflammation and edema in the grey matter lesions [3]. “Normal-appearing grey matter” on MRI thus represents what proves histopathologically to be a mixture of grey matter lesions and nonlesional tissue. This makes it difficult to characterize the clinical significance of grey matter lesions by MRI. Nevertheless, the presence and extent of “juxtacortical” MS lesions on MRI have been correlated with cognitive loss, depression, and epilepsy [13–17].

Keywords

Multiple Sclerosis Grey Matter Myelin Basic Protein White Matter Lesion Cortical Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Prineas JW, McDonald WI, Franklin RJM (2002) Demyelinating diseases In: Graham DI, Lantos PL (eds) Greenfield’s neuropathology. Arnold, London, pp 471–550Google Scholar
  2. 2.
    Brownell BHJT (1962) The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry 25:315–321PubMedCrossRefGoogle Scholar
  3. 3.
    Kidd D, Barkhof F, McConnell R et al (1999) Cortical lesions in multiple sclerosis. Brain 122( Pt l):17–26PubMedCrossRefGoogle Scholar
  4. 4.
    Peterson JW, Bö L, Mörk SJ et al (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389–400PubMedCrossRefGoogle Scholar
  5. 5.
    Bö L, Vedeler CA, Nyland HI et al (2003) Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 62:723–732PubMedGoogle Scholar
  6. 6.
    Bo L, Vedeler CA, Nyland H et al (2003) Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 9:323–331PubMedCrossRefGoogle Scholar
  7. 7.
    Geurts JJG, Bö L, Castelijns JA et al (2004) Cortical lesions in multiple sclerosis: a combined post mortem MRI and histopathology study. AJNR Am J Neuroradiol (in press)Google Scholar
  8. 8.
    Sander M (1898) Hirnrindenbefunde bei multipler Sklerose. Monatschr Psychiatr Neurol IV:427–436CrossRefGoogle Scholar
  9. 9.
    Dinkier (1904) Zur Kasuistik der multiplen Herdsklerose des Gehirns und Ruckenmarks. Dtsch Zeitschr Nervenheilkd 26:233–247CrossRefGoogle Scholar
  10. 10.
    Schob F (1907) Ein Beitrag zur patologischen Anatomie der multiplen Sklerose. Monatschr Psychiatr Neurol 22:62–87CrossRefGoogle Scholar
  11. 11.
    Dawson JW (1916) The Histology Of Disseminated Sclerosis. Trans R Soc Edin L:517–774Google Scholar
  12. 12.
    Newcombe J, Hawkins CP, Henderson CL et al (1991) Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 114:1013–1023Google Scholar
  13. 13.
    Thompson AJ, Kermode AG, Moseley IF et al (1993) Seizures due to multiple sclerosis: seven patients with MRI correlations. J Neurol Neurosurg Psychiatry 56:1317–1320PubMedCrossRefGoogle Scholar
  14. 14.
    Moriarty DM, Blackshaw AJ, Talbot PR et al (1999) Memory dysfunction in multiple sclerosis corresponds to juxtacortical lesion load on fast fluid-attenuated inversionrecovery MR images. AJNR Am J Neuroradiol 20:1956–1962PubMedGoogle Scholar
  15. 15.
    Lazeron RH, Langdon DW, Filippi M et al (2000) Neuropsychological impairment in multiple sclerosis patients: the role of (juxta) cortical lesion on FLAIR. Mult Scler 6:280–285PubMedGoogle Scholar
  16. 16.
    Rovaris M, Filippi M, Minicucci L et al (2000) Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol 21:402–408PubMedGoogle Scholar
  17. 17.
    Feinstein A, Roy P, Lobaugh N et al (2004) Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 62:586–590PubMedCrossRefGoogle Scholar
  18. 18.
    Itoyama Y, Sternberger NH, Webster HD et al (1980) Immuno-cytochemical observations on the distribution of myelin-associated glycoprotein and myelin basic-protein in multiple-sclerosis lesions. Ann Neurol 7:167–177PubMedCrossRefGoogle Scholar
  19. 19.
    Lumsden CE (1970) The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology. Multiple sclerosis and other demyelinating diseases. Amsterdam, North Holland, pp 217–309Google Scholar
  20. 20.
    Hellwig B (1993) How the myelin picture of the human cerebral cortex can be computed from cytoarchitectural data. A bridge between von Economo and Vogt. J Hirnforsch 34:387–402PubMedGoogle Scholar
  21. 21.
    Cifelli A, Arridge M, Jezzard P et al (2002) Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 52:650–653PubMedCrossRefGoogle Scholar
  22. 22.
    Evangelou N, Konz D, Esiri MM et al (2001) Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 124:1813–1820PubMedCrossRefGoogle Scholar
  23. 23.
    Wegner C, Esiri MM, Palace J, Matthews PM (2003) Synaptic loss in cortical lesions of multiple sclerosis. Mult Scler 9:P612CrossRefGoogle Scholar
  24. 24.
    Bö L, van den Berg H, van der Valk P (2003) Meningeal inflammation, a cause of demyelination in multiple sclerosis? J Pathol 201:8A–8AGoogle Scholar

Copyright information

© Springer-Verlag Italia 2004

Authors and Affiliations

  • B. P. Brink
  • S. J. Mork
  • P. Van Der Valk
  • L. Bo

There are no affiliations available

Personalised recommendations